Annual report
Reg. 34 (1) Annual Report. 26 Sep - Company issued corrigendum and revised FY2025-26 annual report before 33rd AGM.
Source: Bse
Fischer Medical Ventures Limited (FISCHER)
Small CapPharma stocks · Small cap · NSE
Fischer Medical Ventures Limited operates in Medical Devices, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹28.27
-1.39 · -4.69%
Market cap ₹2,292 Cr
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result14 Aug, 08:43 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
52Neutralfull bear SMA stack · SMA20 -9.8% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
FISCHERD candles · FIT view-23.9%Latest close ₹28.27 on 2026-10-19
Bar
-4.2%
RSI
23
MACD hist
-0.30
52W pos
0%
2026-10-19O ₹29.50H ₹29.69L ₹28.11C ₹28.27Vol 4.1L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
FISCHERNifty PharmaNifty 500
- FISCHER
- -29.2%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -23.6 pp
Chart stats
19 Oct 2026- From 52W high
- -76.8%
- 52W range position
- 0%
- ATR (14)
- 5.5%
- Volume vs 20D
- 0.38x
- Avg traded value
- ₹3.5 Cr
- 20D price channel
- ₹28.1 - ₹36.2
₹121.7
₹28.1 - ₹121.7
₹1.6
Latest completed session
20-session average
36.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED30
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +249.5% · PAT -22.0% YoY
Technical
Neutral52
Price trend and sector-relative-strength timing.
Valuation
Legacy model-65.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence62
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -22% YoY · margin compression · Rev +249% YoY
Filed 14 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹81.9 Cr | +249.5% | -16.0% |
| EBITDA | ₹11.3 Cr | +182.0% | +398.4% |
| Operating margin | 13.7% | -329 bps | +1760 bps |
| PAT | ₹3.8 Cr | -22.0% | NDF |
| PAT margin | 4.6% | -1610 bps | +1738 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 93.60
- P/B
- 5.58
- EV/EBITDA
- 48.96
- Market Cap
- 2292.00Cr
Profitability
- ROE
- 8.91%
- ROCE
- 11.40%
- ROA
- 3.58%
- Dividend Y
- 0.15%
Growth (CAGR)
- Revenue 5Y
- 22.00%
- EPS 5Y
- 22.00%
- Revenue 3Y
- 44.00%
- EPS 3Y
- 55.00%
Balance Sheet
- Debt/Equity
- 0.28
- Interest Coverage
- 5.00×
- Altman Z
- 6.45
- Book Value
- 5.88
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -101.00 Cr
- EPS TTM
- 0.38
Shareholding
- Promoter Hold
- 63.09%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 2%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 308+177.5% vs prev
Net Profit
₹ CrLatest: 31.0+3000.0% vs prev
Return on Equity
%Latest: 8.1+2583.3% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 23. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~10.9% over last month) — short-term momentum negative.
- RSI(14) at 23 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
3
RS percentile
Stage 4 Downtrend
1M return
-14.7%
3M return
-29.2%
6M return
-24.3%
1Y return
-74.1%
RS 1D
0
RS 20D
-1
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 22.8% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.7%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 25.6-3.69%
RS vs Nifty 50026
Valuation & peers
U-Score 30 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 30 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth15/25
Quality2/20
Balance Sheet9/15
Cash Flow0/10
Piotroski
6/9 (+3)
Penalties
1
Raw sum
30
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
30/100 · legacy band OVERVALUED
Positive drivers
- Growth contributes 15/25 to the score.
- Balance sheet contributes 9/15 to the score.
- Quality contributes 2/20 to the score.
Main drags
- Fair-value margin of safety is negative at -65.3%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
93.6
PB
5.6
EV/EBITDA
49.0
ROE
8.9%
ROCE
11.4%
FCF Yield
—
Debt/Equity
0.3
MoS
-65.3%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
30
Previous: 30
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-65.3%
Previous: -65.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
30
30
30
30
30
30
30
30
30
30
30
30
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹7.09
-298.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹17.1
-65.3% MoS
PEG
2.66
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KRSNAA
Small
Krsnaa Diagnostics Limited
Healthcare Services
match 142
30
18.6
10.9%
-277%
OVERVALUED
SURAKSHA
Small
Suraksha Diagnostic Limited
Healthcare Services
match 140
52
48.3
14.2%
+4%
FAIR VALUE
SAKAR
Small
Sakar Healthcare Limited
Healthcare Services
match 139
38
62.1
10.0%
-26%
WATCHLIST
INDOCO
Small
Indoco Remedies Limited
Healthcare Services
match 139
18
—
-9.4%
-10580%
OVERVALUED
VENUSREM
Small
Venus Remedies Limited
Healthcare Services
match 137
67
20.5
15.6%
+59%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Fischer Medical Ventures Limited operates in Medical Devices, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
62Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 35th percentile of the scored universe and 24th percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
10 docs text-extracted · 2 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
35th percentile
overall median 67 · Pharma: 24th pctile, median 70 · Small: 40th pctile, median 66
Evidence depth
Financial-only
10 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
90
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 63.1%.
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 1.3%.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Operating cash flow is negative at ₹-101 Cr.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸Only 0 years of positive FCF.
- ▸1/4 latest quarters had positive YoY PAT growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Fischer Medical Ventures Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Allotment 17 Aug - Board allotted 4,54,210 equity shares on warrant conversion to promoter FMV Holdings Pte Ltd for Rs.79.71 lakh.
Source: Bse
AnnouncementQ4 2026
Q4 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 15 May - Newspaper Advertisement- Special Window for Re-lodgement of Transfer requests for physical shares
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Sep - Newspaper Advertisement for completion of dispatch, of Annual Report FY 2025-26, to Shareholders
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.